

SKYEPHARMA PLC  
Form 6-K  
March 03, 2006

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March, 2006

SkyePharma PLC

---

(Translation of registrant's name into English)

---

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

Edgar Filing: SKYEPHARMA PLC - Form 6-K

**For Immediate Release**

SkyePharma PLC

## **Clarification of Financial Position**

LONDON, UK, 3 March 2006 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) wishes to clarify its financial results for the NAV group in the media today.

Under the UK Listing Rules a company is required to report if there is a material change in its no material change in SkyePharma's financial condition since the working capital statement in the

Yesterday the NAV group issued a document and SkyePharma responded to all its claims proving the governance are completely without foundation. However, verbally the NAV group has made outrageous position.

No mention of the alleged cash problem was included in the NAV group's written release. This tactic is this small collection of shareholders are using which continue to destroy value in Sky the damage these slurs are causing.

Jerry Karabelas said:

"There is no cash problem.

"The behaviour of the NAV group is disgraceful. Having failed to make their innuendos over spread rumours which are simply untrue.

"The time has come for other shareholders to stand up for SkyePharma before the NAV group do any

For further information please contact:

SkypePharma PLC

+44 207 491 1777

Frank Condella, Chief Executive Officer

+44 207 491 5124

Sandra Haughton, US Investor Relations

+1 212 753 5780

Buchanan Communications  
Tim Anderson / Mark Court

+44 207 466 5000

### **Notes for editors:**

---

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technology and more effective drug formulations. There are now eleven approved products incorporating Skye's oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. [www.skyepharma.com](http://www.skyepharma.com).

Certain statements in this news release are forward-looking statements and are made in reliance U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations statements are reasonable, it can give no assurance that these expectations will materialize. Because of risks and uncertainties, actual results may vary significantly from those expressed or implied based upon a number of factors, which are described in SkyePharma's 20-F and other documents on file. There are numerous factors that could cause differences between actual results and those implied by the forward-looking statements contained herein, without limitation, risks related to the development of new products, risks related to obtaining approvals for existing, new or expanded indications of existing and new products, risks related to SkyePharma's ability to commercialize products on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability to maintain or expand market share in the face of changes in customer requirements, competition and other factors, including the risk of non-compliance with applicable laws and regulations, the risk of product liability claims, risks related to the ownership and protection of intellectual property rights, and other risks detailed in the Company's periodic reports filed with the SEC.

**Edgar Filing: SKYEPHARMA PLC - Form 6-K**

*risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to update forward-looking statement to reflect events or circumstances after the date of this release.*

END

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ Douglas Parkhill

Name: Douglas Parkhill  
Title: Company Secretary

Date: March 3, 2006